SCHEMBL4041393

SCHEMBL4041393

COc1ccc(-c2c/c(=N/O)c3cccc(C)c3o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
LMNA P02545 5/20 0.51
MAPK1 P28482 4/20 0.51
KDM4E B2RXH2 4/20 0.51
RAB9A P51151 2/20 0.51
CYP1A1 P04798 4/20 0.49
CYP1A2 P05177 4/20 0.49
CYP1B1 Q16678 4/20 0.49
TDP1 Q9NUW8 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
AURKA O14965 1/20 0.46
DAPK3 O43293 1/20 0.46
MAP4K4 O95819 1/20 0.46
RET P07949 1/20 0.46
IGF1R P08069 1/20 0.46
MET P08581 1/20 0.46
PIM1 P11309 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13797838 1.00 MAPT (0.51) MAPTLMNAMAPK1KDM4ERAB9A
SCHEMBL4041398 1.00 MAPT (0.51) MAPTLMNAMAPK1KDM4ERAB9A
SCHEMBL13797837 0.85 CYP1A1 (0.52) MAPTLMNAMAPK1KDM4ERAB9A
SCHEMBL13797828 0.85 CYP1A1 (0.66) MAPTMAPK1KDM4ERAB9ACYP1A1
SCHEMBL535362 0.80 CYP1A1 (0.68) MAPTLMNAKDM4ERAB9ACYP1A1
SCHEMBL4040956 0.80 MAOB (0.64) MAPTLMNAMAPK1KDM4ERAB9A
SCHEMBL13797852 0.75 KCNA5 (0.66) MAPTLMNAMAPK1KDM4ERAB9A
SCHEMBL4040414 0.75 KCNA5 (0.66) MAPTLMNAMAPK1KDM4ERAB9A
SCHEMBL4040416 0.75 KCNA5 (0.66) MAPTLMNAMAPK1KDM4ERAB9A
SCHEMBL13797831 0.72 MAOB (0.56) MAPTLMNAMAPK1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547794-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-06-16 US disclosed
EP-1615906-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2006-01-18 EP disclosed
WO-2004092154-A1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-10-28 WO disclosed
US-20040198750-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198750-A1 Compositions useful as inhibitors of protein kinases MAP3K20, MAP3K6, PACSIN2 MAPT 1295/4885LMNA 1800/4885MAPK1 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.